The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).
 
Erin Van Blarigan
No Relationships to Disclose
 
Chao Ma
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Alan P. Venook
Consulting or Advisory Role - Array BioPharma; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Genentech; Roche
 
Kimmie Ng
Consulting or Advisory Role - Array BioPharma; BiomX; Seagen; X-Biotix Therapeutics
Research Funding - Evergrande Group (Inst); Janssen (Inst); Pharmavite (Inst); Revolution Medicines (Inst)
 
Donna Niedzwiecki
No Relationships to Disclose
 
Edward L. Giovannucci
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Federico Innocenti
Consulting or Advisory Role - Emerald Lake Safety; Symberix
Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.; United States Provisional Application ”Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on September 20, 2019, serial number 62/903,442.
 
James Edward Shaw
No Relationships to Disclose
 
Blase N. Polite
Honoraria - American Journal of Managed Care; HMP; Physicans' Education Resource; Simon-Kucher and Partners
Consulting or Advisory Role - Cancer Expert Now; Natera
Speakers' Bureau - Natera
Research Funding - Merck
Travel, Accommodations, Expenses - Institute for Clinical and Economic Review; Tapestry Pharmaceuticals
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Elion Oncology; Genentech; Merck
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Taiho Pharmaceutical
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Robert J. Mayer
Consulting or Advisory Role - Bayer
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)
 
Charles S. Fuchs
Leadership - CytomX Therapeutics; EvolveImmune Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Entrinsic Health; EvolveImmune Therapeutics
Consulting or Advisory Role - Agios; Amylin; AstraZeneca; AstraZeneca; Bain Capital; CytomX Therapeutics; Daiichi-Sankyo; Entrinsic Health; EvolveImmune Therapeutics; Genentech/Roche; Lilly; Merck; Sanofi; Taiho Pharmaceutical; Unum Therapeutics
Expert Testimony - Amylin; Lilly
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Taiho Pharmaceutical
Research Funding - Boston Biomedical (Inst)